Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04736719 · ClinicalTrials.gov registry record
Replication of the AMPLIFY Anticoagulant Trial in Healthcare Claims Data
A clinical trial of Venous Thromboembolism, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- 19,002
- Enrollment target
- 1
- Study location
NCT04736719: Completed study of Venous Thromboembolism, sponsored by Brigham and Women's Hospital.
NCT04736719 is a study of Venous Thromboembolism that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 19,002 participants, above the 5,892-participant average among 47 other Venous Thromboembolism trials with a reported enrollment target (223% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04736719, a study of Venous Thromboembolism, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- 19,002 participants
- Enrollment target
- 1
- Study location
Study Summary
Investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.
Conditions Studied
Interventions
- DRUG Apixaban
- DRUG Warfarin
Study Locations (1)
Massachusetts
- Brigham and Women's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19,002 participants |
| Start Date | 2020-09-22 |
| Est. Completion | 2021-02-18 |
What the finished NCT04736719 record still lists
NCT04736719 is an observational study that tracks outcomes without assigning an intervention. Its 19,002 participants enrollment target places it among the larger protocols in the corpus, above the 5,892-participant average among 47 other Venous Thromboembolism trials with a reported enrollment target (223% higher).
The record links to 1 condition, with Venous Thromboembolism appearing as the primary indexed condition, and to 2 interventions - of which Apixaban is the first listed.
NCT04736719 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04736719 about?
NCT04736719 is a clinical study titled "Replication of the AMPLIFY Anticoagulant Trial in Healthcare Claims Data". Investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such...
What is the current status of trial NCT04736719?
This trial is currently completed. The enrollment target is 19,002 participants. The study started on 2020-09-22. Estimated completion is 2021-02-18.
What conditions does trial NCT04736719 study?
This clinical trial studies the following conditions: Venous Thromboembolism.
What interventions are being tested in trial NCT04736719?
The interventions under investigation include: Apixaban (DRUG), Warfarin (DRUG).
Who is sponsoring clinical trial NCT04736719?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04736719 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Venous Thromboembolism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04736719's enrollment target sits among peer trials
19,002 4th of 47 higher than 44 of 47 other Venous Thromboembolism trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Venous Thromboembolism trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Glioblastoma Remote Monitoring and Care - Research Protocol
RECRUITING · NA
-
Venous Thromboembolism Prevention in Outpatients With Glioma
RECRUITING · Phase 2
-
PRospective Evaluation of Peripartum Anticoagulation ManaGement for ThrOmboembolism
RECRUITING
-
Intervention to Improve Utilization of Extended Venous Thromboembolism Prophylaxis After Cancer Surgery
RECRUITING · NA
-
Computerized Registry of Patients With Venous Thromboembolism (RIETE)
RECRUITING
-
Evaluation of the SCALED (SCaling AcceptabLE cDs)
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05555095 · 19,331 participants
Examining Digital Health Care Delivery Models Through Medicaid Collaborative
- NCT07152249 · 19,480 participants · NA
Advancing Strategies to Optimize the PerIopeRativE Management of PostOperative Nausea and Vomiting (ASPIRE-PONV) Trial
- NCT04372875 · 18,500 participants · NA
Health Information Technology to Reduce Disparities in Adolescent Health Outcomes: A Pragmatic Trial
- NCT00271180 · 20,000 participants
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI